



Suite 518, Level 5
165-167 Phillip Street
Sydney NSW Australia 2000
PO Box H100
Australia Square NSW Australia 1215
T +61 2 8098 0819
F +61 2 8080 8315
www.mmjphytotech.com.au
info@mmjphytotech.com.au
ABN 91 601 236 417

ASX RELEASE

25 September 2018

Filing statement ahead of MediPharm Labs listing

MMJ PhytoTech Limited (ASX: MMJ) ("MMJ") is pleased to note the filing statement related to the imminent listing, by way of a reverse takeover ("RTO"), of MediPharm Labs, Inc. ("MediPharm Labs") on the TSX Venture Exchange. The filing statement (dated 24 September 2018) can be viewed by entering "POCML 4 Inc" in the Company Name box at:

https://www.sedar.com/search/search_form_pc_en.htm

MMJ notes that on pages 33 and 34 of the filing statement there is a detailed description of the expected sources and uses of the CAD\$20.9 million of available funds to MediPharm Labs on completion of the RTO.

MMJ has invested CAD\$5 million of equity for an approximate shareholding of 6.9% in MediPharm Labs.

Investor and Media Enquiries

Jason Conroy
Chief Executive Officer

About MMJ

MMJ is a global cannabis investment company. MMJ owns a portfolio of minority investments and aims to invest across the full range of emerging cannabis-related sectors including healthcare, technology, infrastructure, logistics, processing, cultivation, equipment and retail. For MMJ's latest investor presentation and news, please visit: <https://www.mmjphytotech.com.au/investors/>